Plasma miRNA-155 Levels Predict Atrial Fibrillation Recurrence after Cardioversion

Prediction of Atrial Fibrillation Recurrence

  • Xiong Zhang Department of Laboratory, the First People’s Hospital of Xianyang City, Xianyang, Shaanxi Province, China
  • Xiao-ping Xiao Department of Laboratory, the Eighth Hospital of Xi’an City, Xi’an, Shaanxi Province, China
  • Xu-ai Ren Department of Cardiology, the First People’s Hospital of Xianyang, Xianyang, Shaanxi Province, China
  • Tao Cui Department of Cardiology, the First People’s Hospital of Xianyang, Xianyang, Shaanxi Province, China
DOI: https://doi.org/10.1532/hsf.2281

Abstract

Background: MicroRNAs (miRNAs) are widely involved in the regulation of physiological processes, such as cell proliferation, differentiation, apoptosis, angiogenesis, and lipid metabolism. They might be associated with the pathological process of atrial fibrillation (AF). The purpose of our study is to investigate whether plasma miRNA-155 levels have a relationship with AF recurrence.

Methods: A total of 110 patients with AF were studied, all with successful cardioversion. We measured the expression of plasma miRNA-155 in the recurrent group (n = 30) and in the nonrecurrent group (n = 80) by quantitative reverse transcription–polymerase chain reaction (qRT-PCR). In addition, the serumal levels of B-type natriuretic peptide (BNP), total cholesterol (TC), and fasting blood glucose (FBG) in the groups were determined by using an automatic biochemical analyzer; and an immunoenzymatic method was applied to determine the serumal levels of tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6). The left atrial diameter (LAD) and left ventricular ejection fraction (EF) of all patients were measured by using echocardiography.

Results: Our RT-PCR analysis found that miRNA-155 was significantly upregulated in the recurrent group compared with the nonrecurrent group. These increases of LAD and the levels of BNP, TNF-α, CRP, and IL-6 in the recurrent group were also revealed to be relative to those in the nonrecurrent group. There were no differences in the levels of TC and FBG, as well as in EF, between the groups. Moreover, miRNA-155 expression was observed to correlate positively with these outcomes of LAD, BNP, TNF-α, CRP, IL-6, and LAD. A diagnostic significance of predicting AF recurrence for plasma miRNA-155 was elucidated via ROC curve analysis.

Conclusions: Our findings revealed that plasma miRNA-155 can present an ability to calculate AF recurrence after cardioversion.

References

imé-Sempé C, Folliguet T, Rücker-Martin C, et al. 1999. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 34:1577-86.

Allessie M, Ausma J, Schotten U. 2002. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54:230-46.

Ausma J, Wijffels M, Thoné F, Wouters L, Allessie M, Borgers M. 1997. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96:3157-63.

Aviles RJ, Martin DO, Apperson-Hansen C, et al. 2003. Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006-10.

Blanco RR, Austin H, Vest RN 3rd, et al. 2012. Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure. J Card Fail 18:717-23.

Cai L, Yin Y, Ling Z, et al. 2013. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 164:82-7.

Casaclang-Verzosa G, Gersh BJ, Tsang TS. 2008. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 51:1-11.

Chang SL, Chen YC, Chen YJ, et al. 2007. Mechanoelectrical feedback regulates the arrhythmogenic activity of pulmonary veins. Heart 93:82-8.

Chugh SS, Havmoeller R, Narayanan K, et al. 2014. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129:837-47.

den Uijl DW, Delgado V, Bertini M, et al. 2011. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart 97:1847-51.

Fichtlscherer S, De Rosa S, Fox H, et al. 2010. Circulating microRNAs in patients with coronary artery disease. Circ Res 107:677-84.

Filipowicz W, Bhattacharyya SN, Sonenberg N. 2008. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102-14.

Genovesi S, Rossi E, Gallieni M, et al. 2015. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 30:491-8.

Hou J, Wang P, Lin L, et al. 2009. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183:2150-8.

January CT, Wann LS, Alpert JS, et al. 2014. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130:2071-104.

Jiang S, Zhang HW, Lu MH, et al. 2010. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119-27.

Kannel WB, Benjamin EJ. 2009. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 27:13-24, vii.

Kannel WB, Wolf PA, Benjamin EJ, Levy D. 1998. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(7 suppl 1):2N-9N.

Katsanos S, Mavrogenis AF, Kafkas N, et al. 2017. Cardiac biomarkers predict 1-year mortality in elderly patients undergoing hip fracture surgery. Orthopedics 40:e417-24.

Kirchhof P, Benussi S, Kotecha D, et al. 2016. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893-962.

Li D, Fareh S, Leung TK, Nattel S. 1999. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100:87-95.

Lu ZJ, Wu JJ, Jiang WL, et al. 2017. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J Gastroenterol 23:976-85.

Marchese P, Bursi F, Delle Donne G, et al. 2011. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr 12:214-21.

Marfella R, Sasso FC, Siniscalchi M, et al. 2013. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol 62:525-30.

Marrouche NF, Wilber D, Hindricks G, et al. 2014. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311:498-506.

Mitrić G, Udy A, Bandeshe H, Clement P, Boots R. 2016. Variable use of amiodarone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. Crit Care 20:90.

Naccarelli GV, Varker H, Lin J, Schulman KL. 2009. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104:1534-9.

Nattel S, Harada M. 2014. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 63:2335-45.

O’Connell RM, Kahn D, Gibson WS, et al. 2010. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33:607-19.

O’Connell RM, Rao DS, Baltimore D. 2012. microRNA regulation of inflammatory responses. Annu Rev Immunol 30:295-312.

O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604-9.

Pison L, Tilz R, Jalife J, Haïssaguerre M. 2016. Pulmonary vein triggers, focal sources, rotors and atrial cardiomyopathy: implications for the choice of the most effective ablation therapy. J Intern Med 279:449-56.

Rebane A, Akdis CA. 2013. MicroRNAs: essential players in the regulation of inflammation. J Allergy Clin Immunol 132:15-26.

Rücker-Martin C, Pecker F, Godreau D, Hatem SN. 2002. Dedifferentiation of atrial myocytes during atrial fibrillation: role of fibroblast proliferation in vitro. Cardiovasc Res 55:38-52.

Sardu C, Santamaria M, Paolisso G, Marfella R. 2015. microRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics 16:1863-77.

Sardu C, Santulli G, Santamaria M, et al. 2017. Effects of alpha lipoic acid on multiple cytokines and biomarkers and recurrence of atrial fibrillation within 1 year of catheter ablation. Am J Cardiol 119:1382-6.

Sinner MF, Stepas KA, Moser CB, et al. 2014. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace 16:1426-33.

van Berkel TJ, Out R, Hoekstra M, Kuiper J, Biessen E, van Eck M. 2005. Scavenger receptors: friend or foe in atherosclerosis? Curr Opin Lipidol 16:525-35.

Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. 1995. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 25:1155-60.

Verheule S, Tuyls E, van Hunnik A, Kuiper M, Schotten U, Allessie M. 2010. Fibrillatory conduction in the atrial free walls of goats in persistent and permanent atrial fibrillation. Circ Arrhythm Electrophysiol 3:590-9.

Wang J, Song S, Xie C, et al. 2015. MicroRNA profiling in the left atrium in patients with non-valvular paroxysmal atrial fibrillation. BMC Cardiovasc Disord 15:97.

Xu J, Cui G, Esmailian F, et al. 2004. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109:363-8.

Published
2019-03-11
How to Cite
Zhang, X., Xiao, X.- ping, Ren, X.- ai, & Cui, T. (2019). Plasma miRNA-155 Levels Predict Atrial Fibrillation Recurrence after Cardioversion. The Heart Surgery Forum, 22(2), E140-E148. https://doi.org/10.1532/hsf.2281
Issue
Vol 22 No 2 (2019)
Section
Articles

Author Disclosure & Copyright Transfer Agreement

In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.

A current form follows:

The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.

However, Publisher grants back to the author(s) the following:

  1. The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
  2. The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
  3. The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
  4. The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
  5. The right to make oral presentations of material from this work.

Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.

I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.

I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).

I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.

Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).